• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Drug Pricing Provisions Under the IRA and What They Mean for the Pharmaceutical Supply Chain | Asembia Specialty Pharmacy Summit


Kelsey Lang, principal of Avalere, breaks down the three provisions of the Inflation Reduction Act, which was discussed today at the annual Asembia Specialty Pharmacy Summit in Las Vegas.

There are currently three provisions part of the inflation Reduction Act.

Kelsey Lang, principal of Avalere, along with a couple members of her team, addressed these provisions today at the annual Asembia Specialty Pharmacy Summitt in Las Vegas.

In addition, her team discussed the types of things plans, manufacturers, pharmacies and other stakeholders should be planning for, as the law continues to be implemented over the next several months.

The provisions that are underway and affecting these pharamcy groups are a penalty for manufacturers that increase prices faster than the rate of inflation. This provision happens to be in effect today. The Act also requires Medicare to redesign the Part D benefit starting in 2025, as well as gives the Medicare program the authority to directly negotiate drug prices for the first time beginning in 2026.

"So thinking ahead to these other provisions, CMS is implementing policies now and making policy decisions that are going to impact things like how manufacturers approach product development, the benefit design in the party program, contracting for drugs, as well as access to care," said Lang in the video interview.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.